K-ras is essential for embryogenesis and its mutations are involved in human developmental syndromes and cancer. To determine the consequences of K-ras activation in urothelium, we used uroplakin-II (UPK II) promoter driven Cre recombinase mice and generated mice with mutated KrasG12D allele in the urothelium (UPK II-Cre;LSL-K-rasG12D). The UPK II-Cre;LSL-K-rasG12D mice died neonatally due to lung morphogenesis defects consisting of simplification with enlargement of terminal air spaces and dysmorphic pulmonary vasculature. A significant alteration in epithelial and vascular basement membranes, together with fragmentation of laminin, points to extracellular matrix degradation as the causative mechanism of alveolar and vascular defects. Our data also suggest that altered protease activity in amniotic fluid might be associated with matrix defects in lung of UPK II-Cre;LSL-K-rasG12. These defects resemble those observed in early stage human neonatal bronchopulmonary dysplasia (BPD), although the relevance of this new mouse model for BPD study needs further investigation.
References
[1]
Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7: 295–308. doi: 10.1038/nrc2109
[2]
Janssen KP, Abal M, El Marjou F, Louvard D, Robine S (2005) Mouse models of K-ras-initiated carcinogenesis. Biochim Biophys Acta 1756: 145–154. doi: 10.1016/j.bbcan.2006.01.005
[3]
Denayer E, de Ravel T, Legius E (2008) Clinical and molecular aspects of RAS related disorders. J Med Genet 45: 695–703. doi: 10.1136/jmg.2007.055772
[4]
Esteban LM, Vicario-Abejon C, Fernandez-Salguero P, Fernandez-Medarde A, Swaminathan N, et al. (2001) Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol 21: 1444–1452. doi: 10.1128/mcb.21.5.1444-1452.2001
[5]
Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, et al. (1997) K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 11: 2468–2481. doi: 10.1101/gad.11.19.2468
[6]
Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, et al. (2003) Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4: 111–120. doi: 10.1016/s1535-6108(03)00191-0
[7]
Schubbert S, Bollag G, Lyubynska N, Nguyen H, Kratz CP, et al. (2007) Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol 27: 7765–7770. doi: 10.1128/mcb.00965-07
[8]
Shaw AT, Meissner A, Dowdle JA, Crowley D, Magendantz M, et al. (2007) Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev 21: 694–707. doi: 10.1101/gad.1526207
[9]
Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, et al. (2004) Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5: 375–387. doi: 10.1016/s1535-6108(04)00085-6
[10]
Zhang ZT, Pak J, Huang HY, Shapiro E, Sun TT, et al. (2001) Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 20: 1973–1980. doi: 10.1038/sj.onc.1204315
[11]
Cordon-Cardo C (2008) Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl: 154–165.
[12]
Oxford G, Theodorescu D (2003) Review Article: The Role of Ras Superfamily Proteins in Bladder Cancer Progression. J Urol 170: 1987–1993. doi: 10.1097/01.ju.0000088670.02905.78
[13]
Yang X, La Rosa FG, Genova EE, Huber K, Schaack J, et al. (2013) Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia. PLoS One 8: e74809. doi: 10.1371/journal.pone.0074809
[14]
Steinestel J, Cronauer M V, Müller J, Al Ghazal A, Skowronek P, et al. (2013) Overexpression of p16(INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection. PLoS One 8: e65189. doi: 10.1371/journal.pone.0065189
Baraldi E, Filippone M (2007) Chronic lung disease after premature birth. N Engl J Med 357: 1946–1955. doi: 10.1056/nejmra067279
[17]
Ayala de la Pena F, Kanasaki K, Kanasaki M, Tangirala N, Maeda G, et al. (2011) Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem 286: 20778–20787. doi: 10.1074/jbc.m110.198069
Mo L, Cheng J, Lee EY, Sun TT, Wu XR (2005) Gene deletion in urothelium by specific expression of Cre recombinase. Am J Physiol Ren Physiol 289: F562–8. doi: 10.1152/ajprenal.00368.2004
[21]
Schittny PH. J B (2003) Morphogenesis of the mammalian lung: aspects of structure and extracellular matrix components. In: Massaro D Chambon P, editors MGD, editor. Lung development and regeneration. New York: Marcel Dekker Inc. pp. 275–317.
[22]
Roth-Kleiner M, Post M (2005) Similarities and dissimilarities of branching and septation during lung development. Pediatr Pulmonol 40: 113–134. doi: 10.1002/ppul.20252
[23]
Kitagawa H, Pringle KC, Zucollo J, Koike J, Nakada K, et al. (2000) Early fetal obstructive uropathy produces Potter's syndrome in the lamb. J Pediatr Surg 35: 1549–1553. doi: 10.1053/jpsu.2000.18305
Vizan P, Boros LG, Figueras A, Capella G, Mangues R, et al. (2005) K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. Cancer Res 65: 5512–5515. doi: 10.1158/0008-5472.can-05-0074
[26]
McGowan EC, Kostadinov S, McLean K, Gotsch F, Venturini D, et al. (2009) Placental IL-10 dysregulation and association with bronchopulmonary dysplasia risk. Pediatr Res 66: 455–460. doi: 10.1203/pdr.0b013e3181b3b0fa
[27]
Wang XQ, Li H, Van Putten V, Winn RA, Heasley LE, et al. (2009) Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9. Mol Biol Cell 20: 791–800. doi: 10.1091/mbc.e08-07-0732
[28]
Underwood MA, Gilbert WM, Sherman MP (2005) Amniotic Fluid: Not Just Fetal Urine Anymore. J Perinatol 25: 341–348. doi: 10.1038/sj.jp.7211290
[29]
Lin JH, Zhao H, Sun TT (1995) A tissue-specific promoter that can drive a foreign gene to express in the suprabasal urothelial cells of transgenic mice. Proc Natl Acad Sci U S A 92: 679–683. doi: 10.1073/pnas.92.3.679
[30]
Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, et al. (2008) Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 14: 6610–6617. doi: 10.1158/1078-0432.ccr-08-1136
[31]
Harding R, Bocking AD, Sigger JN (1986) Influence of upper respiratory tract on liquid flow to and from fetal lungs. J Appl Physiol 61: 68–74.
[32]
Bhandari A, Bhandari V (2009) Pitfalls, Problems, and Progress in Bronchopulmonary Dysplasia 10.1542/peds.2008-1962. Pediatrics 123: 1562–1573. doi: 10.1542/peds.2008-1962
[33]
Backstrom E, Hogmalm A, Lappalainen U, Bry K (2011) Developmental stage is a major determinant of lung injury in a murine model of bronchopulmonary dysplasia. Pediatr Res 69: 312–318. doi: 10.1203/pdr.0b013e31820bcb2a
[34]
DeLisser HM, Helmke BP, Cao G, Egan PM, Taichman D, et al. (2006) Loss of PECAM-1 function impairs alveolarization. J Biol Chem 281: 8724–8731. doi: 10.1074/jbc.m511798200
[35]
Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, et al. (2002) Loss of HIF-2[alpha] and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. 8: 702–710. doi: 10.1038/nm721
[36]
Thebaud B, Abman SH (2007) Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med 175: 978–985. doi: 10.1164/rccm.200611-1660pp
[37]
Aghai ZH, Arevalo R, Lumicao L, Lesser M, Shi Q, et al. (2002) Basement membrane biomarkers in very low birth weight premature infants. Association with length of NICU stay and bronchopulmonary dysplasia. Biol Neonate 81: 16–22. doi: 10.1159/000047179
[38]
Ekekezie II, Thibeault DW, Simon SD, Norberg M, Merrill JD, et al. (2004) Low levels of tissue inhibitors of metalloproteinases with a high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio are present in tracheal aspirate fluids of infants who develop chronic lung disease. Pediatrics 113: 1709–1714. doi: 10.1542/peds.113.6.1709
[39]
Podowski M, Calvi CL, Cheadle C, Tuder RM, Biswals S, et al. (2009) Complex Integration of Matrix, Oxidative Stress, and Apoptosis in Genetic Emphysema 10.2353/ajpath.2009.080870. Am J Pathol 175: 84–96. doi: 10.2353/ajpath.2009.080870
[40]
Yao H, Arunachalam G, Hwang JW, Chung S, Sundar IK, et al. (2010) Extracellular superoxide dismutase protects against pulmonary emphysema by attenuating oxidative fragmentation of ECM. Proc Natl Acad Sci U S A 107: 15571–15576. doi: 10.1073/pnas.1007625107
[41]
McGuire JK, Li Q, Parks WC (2003) Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 162: 1831–1843. doi: 10.1016/s0002-9440(10)64318-0
[42]
De Paepe ME, Mao Q, Powell J, Rubin SE, DeKoninck P, et al. (2006) Growth of pulmonary microvasculature in ventilated preterm infants. Am J Respir Crit Care Med 173: 204–211. doi: 10.1164/rccm.200506-927oc
[43]
Thebaud B, Ladha F, Michelakis ED, Sawicka M, Thurston G, et al. (2005) Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization. Circulation 112: 2477–2486. doi: 10.1161/circulationaha.105.541524
[44]
Huang Y, Song N, Ding Y, Yuan S, Li X, et al. (2009) Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res 69: 7529–7537. doi: 10.1158/0008-5472.can-08-4382
[45]
Deng FM, Ding M, Lavker RM, Sun TT (2001) Urothelial function reconsidered: a role in urinary protein secretion. Proc Natl Acad Sci U S A 98: 154–159. doi: 10.1073/pnas.98.1.154
